Colorectal News and Research

RSS

Chemotherapy drug sunitinib promising for HIV-positive cancer patients

Preliminary findings from a unique study with sunitinib suggest that it might be possible to tweak the dosage of chemotherapy drugs used to treat HIV-positive cancer patients to achieve therapeutic benefit. Given the type of drug cocktail patients use to treat their HIV, much more or considerably less chemotherapy may be warranted, say the researchers, part of the NCI-supported AIDS Malignancy Consortium (AMC). The trial design is being presented at the 2010 annual meeting of the American Society of Clinical Oncology (ASCO).

8 Jun 2010

Aeterna Zentaris presents data of perifosine Phase 1 trial for recurrent pediatric solid tumors at ASCO

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that Phase 1 data of perifosine (KRX-0401) in recurrent pediatric solid tumors was presented yesterday in the pediatric solid tumor poster discussion session held at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago.

8 Jun 2010

GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010

GTx, Inc. today presented additional results from the Ostarine™ Phase IIb study demonstrating an improvement in quality of life (fatigue and anorexia) in cancer patients with muscle wasting (cancer cachexia) who demonstrated improvement in functional performance as measured by stair climb. Ostarine (GTx-024) is GTx's lead selective androgen receptor modulator (SARM) which the company is developing for the treatment of cancer cachexia.

8 Jun 2010

Interim results from Micromet's MT110 BiTE antibody Phase 1 trial presented at ASCO

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced the presentation of updated interim results from a Phase 1 trial of the Company's BiTE antibody MT110 in patients with advanced solid tumors.

8 Jun 2010

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Synta Pharmaceuticals Corp. announced that clinical results for two Phase 1 trials of STA-9090 in solid tumors, as well as 12 month updated survival results from the SYMMETRY trial of elesclomol in metastatic melanoma, were presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).

8 Jun 2010

Encouraging healthy lifestyle changes helps reduce aging relative's risk of cancer, say experts

Family members can help reduce an aging relative's risk of cancer by encouraging healthy lifestyle changes, according to experts at The University of Texas MD Anderson Cancer Center.

8 Jun 2010

Targeted therapy that benefits patients with metastatic colon cancer fails to help patients with stage III cancer

To the surprise of researchers at Mayo Clinic who led a national clinical trial, a targeted therapy that provides benefit to patients with metastatic colon cancer has failed to help patients with less advanced, stage III cancer. In fact, patients who used the agent, cetuximab, with chemotherapy had outcomes slightly inferior to patients treated with chemotherapy alone.

7 Jun 2010

Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2010

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today preliminary clinical data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

7 Jun 2010

Phase 1 study data of Keryx' perifosine for recurrent pediatric solid tumors presented at ASCO

Keryx Biopharmaceuticals, Inc. today announced that Phase 1 data of KRX-0401 (perifosine) in recurrent pediatric solid tumors was presented yesterday in the pediatric solid tumor poster discussion session held at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place in Chicago, IL.

7 Jun 2010

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

Plexxikon announced today the results of a Phase 1 extension study in metastatic colorectal cancer that showed clinical activity of PLX4032 as a single agent in this hard-to-treat patient population. PLX4032 is a novel, oral small molecule targeting an oncogenic BRAF mutation found in over 50 percent of melanomas, about 10 percent of colorectal cancers and eight percent of all solid tumors.

7 Jun 2010

bioTheranostics presents positive outcomes from CancerTYPE ID, Breast Cancer Index clinical studies

bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID® and Breast Cancer Index® molecular oncology tests. Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago.

7 Jun 2010

USC to present promising new findings in cancer research at 2010 ASCO

Faculty at the University of Southern California (USC) and USC Norris Comprehensive Cancer Center will present promising new findings in a number of cancer research areas at the 2010 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from June 4-8.

5 Jun 2010

PEB's European licensee SDX completes clinical trial for prognostic gene signature for colorectal cancer

Pacific Edge (PEB), a New Zealand-based biomedical company, today announced the successful completion of the European clinical trial for their prognostic gene signature for colorectal cancer. The clinical trial results showed a successful outcome that enables patients diagnosed with UICC stage II or UICC stage III colorectal cancer and with a high risk of disease progression to be identified and treated more appropriately.

5 Jun 2010

ASGE issues guidelines on ethnicity, gastrointestinal diseases and endoscopic procedures

The American Society for Gastrointestinal Endoscopy (ASGE) has issued guidelines addressing ethnicity, gastrointestinal diseases and endoscopic procedures. The guideline suggests that colorectal cancer screening should begin at age 45 for average risk African-American men and women, and that it is recommended that colorectal cancer screening be emphasized for other minority ethnic groups that have lower screening utilization rates.

4 Jun 2010

In 2008, 63% of cancer deaths were in developing countries

By 2030, cancer could claim the lives of 13.3 million annually, almost double the number of patients who died from the illness in 2008, the U.N.'s International Agency for Research on Cancer (IARC) said Tuesday, Agence France-Presse reports.

3 Jun 2010

CCAC applauds Quebec Ministry of Health's colorectal cancer screening pilot

The Colorectal Cancer Association of Canada (CCAC) applauds the decision of the Quebec Ministry of Health and its Minister Yves Bolduc to implement a colorectal cancer screening pilot in anticipation of launching a province wide colorectal cancer screening program.

2 Jun 2010

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

EntreMed, Inc., today announced the publication of preclinical results for its clinical-stage Aurora A/angiogenic kinase inhibitor, ENMD-2076, in human colorectal cancer xenograft models. The results of the study, conducted by EntreMed collaborators at the University of Colorado School of Medicine, were published in the June 1, 2010 issue of Clinical Cancer Research (Vol. 16, Issue 11).

2 Jun 2010

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

Asuragen, Inc., a leader in molecular diagnostics and RNA-based pharmacogenomics services, announced today that it has obtained a non-exclusive license to incorporate the BRAF V600E mutation sequence into Asuragen's molecular diagnostic products. The license was obtained from Johns Hopkins University and includes the use of the BRAF V600E mutation as a component of diagnostic test kits and for use in Asuragen's CLIA laboratory for clinical research and patient testing.

2 Jun 2010

PET and CT colonography combination may provide suitable alternative for detecting polyps: Study

A study published in the June issue of The Journal of Nuclear Medicine shows that positron emission tomography -a molecular imaging technique-combined with computer tomography colonography may provide a suitable alternative for detecting polyps and cancer in the colon. This particular imaging method may be especially desirable for patients because it does not require sedation or bowel preparation.

2 Jun 2010

Major response to preoperative therapy increases survival in pancreatic cancer patients

Cancer of the pancreas--a glandular organ that lies behind the stomach and secretes vital enzymes and hormones--seldom is detected in early stages, making treatment difficult and survival statistics particularly grim. However, new research from Fox Chase Cancer Center finds that patients with pancreatic adenocarcinoma whose tumors respond most to preoperative chemotherapy and radiation survive four times as long, on average, as those whose tumors respond least.

29 May 2010

Colorectal News and Research

Chemotherapy drug sunitinib promising for HIV-positive cancer patients

Aeterna Zentaris presents data of perifosine Phase 1 trial for recurrent pediatric solid tumors at ASCO

GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010

Interim results from Micromet's MT110 BiTE antibody Phase 1 trial presented at ASCO

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Encouraging healthy lifestyle changes helps reduce aging relative's risk of cancer, say experts

Targeted therapy that benefits patients with metastatic colon cancer fails to help patients with stage III cancer

Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2010

Phase 1 study data of Keryx' perifosine for recurrent pediatric solid tumors presented at ASCO

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

bioTheranostics presents positive outcomes from CancerTYPE ID, Breast Cancer Index clinical studies

USC to present promising new findings in cancer research at 2010 ASCO

PEB's European licensee SDX completes clinical trial for prognostic gene signature for colorectal cancer

ASGE issues guidelines on ethnicity, gastrointestinal diseases and endoscopic procedures

In 2008, 63% of cancer deaths were in developing countries

CCAC applauds Quebec Ministry of Health's colorectal cancer screening pilot

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

PET and CT colonography combination may provide suitable alternative for detecting polyps: Study

Major response to preoperative therapy increases survival in pancreatic cancer patients

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News